Sanofi-GSK COVID-19 Vaccine Shows Positive Results in New Trial

Vaccine candidate previously triggered an 'insufficient response' in older adults

The logo of French drug maker Sanofi is seen in Paris on Nov. 30, 2020. Thibault Camus/AP Photo

A COVID-19 vaccine produced in a partnership between Sanofi and GlaxoSmithKline showed strong results in a new trial, the companies announced on May 17.

Interim results from a phase two trial showed the development of antibodies against the CCP (Chinese Communist Party) virus in 95 to 100 percent of volunteers, who ranged in age from 18 to 95.